IL280395B2 - History of tetrahydroquinolino for the treatment of metastatic and chemotherapy-resistant cancer - Google Patents

History of tetrahydroquinolino for the treatment of metastatic and chemotherapy-resistant cancer

Info

Publication number
IL280395B2
IL280395B2 IL280395A IL28039521A IL280395B2 IL 280395 B2 IL280395 B2 IL 280395B2 IL 280395 A IL280395 A IL 280395A IL 28039521 A IL28039521 A IL 28039521A IL 280395 B2 IL280395 B2 IL 280395B2
Authority
IL
Israel
Prior art keywords
compound
halo
cancer
alkyl
alkoxy
Prior art date
Application number
IL280395A
Other languages
English (en)
Hebrew (he)
Other versions
IL280395B1 (en
IL280395A (en
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Publication of IL280395A publication Critical patent/IL280395A/en
Publication of IL280395B1 publication Critical patent/IL280395B1/en
Publication of IL280395B2 publication Critical patent/IL280395B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL280395A 2018-07-31 2019-07-31 History of tetrahydroquinolino for the treatment of metastatic and chemotherapy-resistant cancer IL280395B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712434P 2018-07-31 2018-07-31
PCT/US2019/044278 WO2020028461A1 (en) 2018-07-31 2019-07-31 Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers

Publications (3)

Publication Number Publication Date
IL280395A IL280395A (en) 2021-03-01
IL280395B1 IL280395B1 (en) 2024-12-01
IL280395B2 true IL280395B2 (en) 2025-04-01

Family

ID=67734803

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280395A IL280395B2 (en) 2018-07-31 2019-07-31 History of tetrahydroquinolino for the treatment of metastatic and chemotherapy-resistant cancer

Country Status (8)

Country Link
US (2) US12162855B2 (cg-RX-API-DMAC10.html)
EP (1) EP3830079A1 (cg-RX-API-DMAC10.html)
JP (1) JP7613743B2 (cg-RX-API-DMAC10.html)
CN (1) CN112638881B (cg-RX-API-DMAC10.html)
AU (1) AU2019315444B2 (cg-RX-API-DMAC10.html)
CA (1) CA3107120A1 (cg-RX-API-DMAC10.html)
IL (1) IL280395B2 (cg-RX-API-DMAC10.html)
WO (1) WO2020028461A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL280395B2 (en) 2018-07-31 2025-04-01 Univ Princeton History of tetrahydroquinolino for the treatment of metastatic and chemotherapy-resistant cancer
CA3168533A1 (en) * 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) * 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
JP7781391B2 (ja) * 2021-04-22 2025-12-08 カヨセラ インコーポレイテッド 複素環式化合物及びその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127137A1 (en) * 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
WO2016016316A1 (en) * 2014-08-01 2016-02-04 Nuevolution A/S Compounds active towards bromodomains

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
DE3701277A1 (de) 1987-01-17 1988-07-28 Boehringer Mannheim Gmbh Neue tricyclische benzimidazole, verfahren zu ihrer herstellung und verwendung als arzneimittel
JPH01319453A (ja) * 1988-06-22 1989-12-25 Wakamoto Pharmaceut Co Ltd 新規ベンゾキノン誘導体
EP1626962B1 (en) 2003-05-12 2007-02-28 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
JP4823914B2 (ja) * 2003-11-07 2011-11-24 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Fgfr3の阻害および多発性骨髄腫の治療
EP1718306A2 (en) * 2004-02-20 2006-11-08 Chiron Corporation Modulation of inflammatory and metastatic processes
JP2006349902A (ja) * 2005-06-15 2006-12-28 Fujifilm Holdings Corp 黒白熱現像感光材料
WO2007128884A1 (en) * 2006-05-09 2007-11-15 Oy Jurilab Ltd Novel genes and markers in type 2 diabetes and obesity
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2013027168A1 (en) 2011-08-22 2013-02-28 Pfizer Inc. Novel heterocyclic compounds as bromodomain inhibitors
WO2015173169A1 (en) 2014-05-12 2015-11-19 Fondazione Istituto Italiano Di Tecnologia Substituted benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
IL280395B2 (en) 2018-07-31 2025-04-01 Univ Princeton History of tetrahydroquinolino for the treatment of metastatic and chemotherapy-resistant cancer
CA3168533A1 (en) 2020-01-24 2021-07-29 The Trustees Of Princeton University Heterocyclic compounds and uses thereof
GB202019475D0 (en) 2020-12-10 2021-01-27 Cancer Research Tech Ltd Therapeutic compounds and their use
JP7781391B2 (ja) 2021-04-22 2025-12-08 カヨセラ インコーポレイテッド 複素環式化合物及びその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015127137A1 (en) * 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
WO2016016316A1 (en) * 2014-08-01 2016-02-04 Nuevolution A/S Compounds active towards bromodomains

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
DATAABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE,OHIO,US, 1468571-74-5, 3 October 2013 (2013-10-03) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACT SERVICE ,COLUMBUS,OHIO,US, 1154533-72-8, 9 June 2009 (2009-06-09) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACT SERVICE COLUMBUS,OHIO,US, 1304933-67-2, 3 June 2011 (2011-06-03) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACT SERVICE,COLUMBUS,OHIO,US, 1303823-01-9, 1 June 2011 (2011-06-01) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACT SERVICE,OHIO,US, 1292643-91-8, 10 May 2011 (2011-05-10) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE, COLOMBUS,OHIO,US, 2094147-63-2, 2 May 2017 (2017-05-02) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE,COLUMBUS,OHIO,US, 1306404-60-3, 6 June 2011 (2011-06-06) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE,COLUMBUS,OHIO,US, 1798940-10-9, 10 July 2015 (2015-07-10) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE,COLUMBUS,OHIO,US, 2195663-27-3, 21 March 2018 (2018-03-21) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS SERVICE,OHIO,US, 2195663-27-3, 21 March 2018 (2018-03-21) *
DATABASE REGISTRY [ONLINE] CHEMICAL ABSTRACTS,COLUMBUS,OHIO,US, 1153284-52-6, 7 June 2009 (2009-06-07) *
DATABASE REGISTRY ]ONLINE] CHEMICAL ABSTRACTS SERVICE,COLOMBUS,OHIO,US, 1874534-18-5, 26 February 2016 (2016-02-26) *
DATABASE REGISTRY ]ONLINE] CHEMICAL ABSTRACTS SERVICE,COLOMBUS,OHIO,US, 1875411-98-5, 28 February 2016 (2016-02-28) *

Also Published As

Publication number Publication date
JP2021532158A (ja) 2021-11-25
JP7613743B2 (ja) 2025-01-15
EP3830079A1 (en) 2021-06-09
AU2019315444B2 (en) 2024-10-31
CN112638881A (zh) 2021-04-09
WO2020028461A1 (en) 2020-02-06
IL280395B1 (en) 2024-12-01
US20210155602A1 (en) 2021-05-27
AU2019315444A1 (en) 2021-02-11
IL280395A (en) 2021-03-01
CA3107120A1 (en) 2020-02-06
CN112638881B (zh) 2025-01-07
US12162855B2 (en) 2024-12-10
US20250129046A1 (en) 2025-04-24

Similar Documents

Publication Publication Date Title
US20250129046A1 (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
US11376246B2 (en) Inhibiting mutant IDH-1
US20140364460A1 (en) USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION
US9926290B2 (en) Inhibitors of INV(16) leukemia
Li et al. Novel pyrrolopyridone bromodomain and extra-terminal motif (BET) inhibitors effective in endocrine-resistant ER+ breast cancer with acquired resistance to fulvestrant and palbociclib
WO2021146258A1 (en) Combination therapy for cancer
JP2015529665A (ja) Mth1阻害剤としてのアミノヘテロアリール化合物
KR20250119621A (ko) Dna 폴리머라제 세타 억제제로서의 티아디아졸릴 유도체 및 그의 용도
WO2023213833A1 (en) Use of alc1 inhibitors and synergy with parpi
Sharma et al. First-in-class dual EZH2-HSP90 inhibitor eliciting striking antiglioblastoma activity in vitro and in vivo
JP2022538767A (ja) アセチルCoAシンテターゼ2(ACSS2)阻害剤およびそれを使用する方法
JP2022526844A (ja) 筋肉量及び酸化的代謝を増加させるための組成物及び方法
US11459295B2 (en) 2-beta-naphthyl-acetic acid analogs as AKR1C3 inhibitors and methods of using same
JP7445609B2 (ja) Epac阻害剤としてのチエノ[2,3-b]ピリジン誘導体及びその医薬用途
HK40049062A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
WO2022165432A1 (en) Cullin-ring e3 ubiquitin ligase 4 inhibitor compounds and methods of their use
HK40049062B (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
US12570661B2 (en) Isoform-specific aldehyde dehydrogenase inhibitors
Han et al. Discovery of the thieno [2, 3-b][1, 4] thiazin-2 (3H)-one STING inhibitors
RU2717310C1 (ru) Ингибиторы альдостеронсинтазы на основе производных 2-амино-4H-пиран-3-карбонитрила
HK40097162A (en) Inhibiting mutant idh-1
JP2025521593A (ja) 3βHSD1阻害剤及び組成物ならびにそれらの使用
HK40071406A (en) Inhibitors of met, vegfr and ret for use in the treatment of lung adenocarcinoma
WO2014137420A1 (en) Receptor and kinase modulator screening methods